• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Collegium Pharma (NQ: COLL )

    37.44 +0.35 (+0.94%)
    Streaming Delayed Price Updated: 11:23 AM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 77,430
    Open 37.21
    Bid (Size) 37.35 (2)
    Ask (Size) 37.47 (2)
    Prev. Close 37.09
    Today's Range 37.00 - 37.57
    52wk Range 20.95 - 40.95
    Shares Outstanding 32,213,751
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Organon Stock Sees Relative Strength Rating Rise To 91
    On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
    Via Investor's Business Daily

    Performance

    YTD
    +19.88%
    +19.88%
    1 Month
    +7.31%
    +7.31%
    3 Month
    +12.77%
    +12.77%
    6 Month
    +2.38%
    +2.38%
    1 Year
    +57.24%
    +57.24%

    More News

    Read More
    Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
    Via Investor's Business Daily
    The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
    Via Benzinga
    COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
    Via Benzinga
    Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
    Via Benzinga
    Collegium Reports Second Quarter 2024 Financial Results
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    NASDAQ:COLL is an undervalued gem with solid fundamentals.
    Via Chartmill
    Dr. Reddy's Labs Stock Sees Improved Technical Strength
    Via Investor's Business Daily
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
    Via Chartmill
    Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Participate in Jefferies Global Healthcare Conference
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces $35 Million Accelerated Share Repurchase Program
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Collegium Reports First Quarter 2024 Financial Results
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces CEO Transition
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.